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Herpes simplex virus (HSV)-2 shedding is associated
with increased risk for sexually acquiring HIV.
Because Langerhans cells (LCs), themucosal epithe-
lium resident dendritic cells, are suspected to be one
of the initial target cell types infected byHIV following
sexual exposure, we examined whether and how
HSV-2 affects HIV infection of LCs. Although rela-
tively few HSV-2/HIV-coinfected LCs were detected,
HSV-2 dramatically enhanced the HIV susceptibility
of LCs within skin explants. HSV-2 stimulated epithe-
lial cell production of antimicrobial peptides (AMPs),
including human b defensins and LL-37. LL-37
strongly upregulated the expression of HIV receptors
in monocyte-derived LCs (mLCs), thereby enhancing
their HIV susceptibility. Culture supernatants of
epithelial cells infected with HSV-2 enhanced HIV
susceptibility in mLCs, and this effect was abrogated
by blocking LL-37 production. These data suggest
that HSV-2 enhances sexual transmission of HIV by
increasing HIV susceptibility of LCs via epithelial
cell production of LL-37.
INTRODUCTION
Epidemiologic studies have indicated a strong association
between the acquisition of HIV and other sexually transmitted
diseases (STDs) (Galvin and Cohen, 2004). This link is especially
evident in cases of genital ulcer diseases (GUDs), with a 2- to 11-
fold increase in the rate of HIV acquisition in the presence of GUD
(Cameron et al., 1989; Fleming andWasserheit, 1999). It is widely
recognized that herpes simplex virus type 2 (HSV-2) is a major
cause of GUDs, and more than 50 epidemiologic studies have
now indicated that HSV-2 shedding is associated with increased
risk for acquiring HIV (Wald and Link, 2002). The risk ratio of HIV
acquisition for a person with genital herpes is enhanced from 2 toCell H4 when compared with a person without genital herpes, and
potentially 50%of newHIV infections are considered to be attrib-
utable or worsened by HSV-2 infection (Wald and Link, 2002).
During sexual transmission of HIV, virus crosses mucosal
epithelium and is eventually transmitted to regional lymph nodes,
where it establishes permanent infection. Many studies have
shown that Langerhans cells (LCs) are one of the important initial
cellular targets for HIV, and that this particular type of dendritic
cell (DC) plays a crucial role in disseminating HIV (de Witte
et al., 2007; Kawamura et al., 2005; Lederman et al., 2006; Shat-
tock and Moore, 2003). LCs are present within genital skin (e.g.,
outer foreskin) and mucosal epithelium and, after contact with
pathogens, readily emigrate from tissue to draining lymph
nodes. Immature resident LCs express surface CD4 and
CCR5, but not surface CXCR4 (Zaitseva et al., 1997). These
LCs are readily infected ex vivo with R5 HIV, but not with X4
HIV (Kawamura et al., 2000, 2008; Reece et al., 1998; Zaitseva
et al., 1997). These findings are consistent with previous epide-
miologic observations, which have found that the majority of
HIV strains isolated from newly infected patients are R5 HIV
strains (Zhu et al., 1993). It has been reported that persons
with CCR5 homozygous defects are largely protected from
sexually acquiring HIV (Liu et al., 1996).
Clinical trials performed over the last several years have shown
that circumcision greatly reduces the probability of penile HIV
transmission, suggesting that the foreskin is an important portal
of HIV entry (Auvert et al., 2005; Bailey et al., 2007; Gray et al.,
2007). Although the mechanism leading to protection remains
undefined, several ex vivo experiments with foreskin explants
have indicated that CD4 T lymphocytes and LCs within foreskin
epidermis are initial target cells for HIV (Fahrbach et al., 2010;
Ganor et al., 2010; Grivel et al., 2011; Zhou et al., 2011).
In primate models of simian immunodeficiency virus (SIV)
infection, there is controversy regarding which cells in the genital
mucosa are initially infected by SIV. Studies have demonstrated
that the primary infected cells present in the lamina propria of the
cervicovaginal mucosa 48–72 hr after intravaginal exposure to
SIV are T cells or submucosal DCs, but not epithelial LCs (Spira
et al., 1996; Zhang et al., 1999). When vaginal tissue was exam-
ined within 1 hr following vaginal inoculation, however, up toost & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Inc. 77
Figure 1. HSV-2-Infected Epithelial Cells Augment HIV Infection in LCs
(A–C) Epithelial sheets were preincubated with HSV-2 and then exposed to R5 HIV. Epithelial sheets were floated on culture medium to allow migration of LCs
from the explants. Emigrating cells from the epidermal sheets were collected 3 days following HIV exposure. HIV-infected LCs were assessed by HIV p24
intracellular staining in langerin+ CD11c+ LCs (A) and the results of 11 separate experiments with different donors are summarized (B). HSV and/or HIV-infected
LCs were assessed by HIV p24 and HSV gD intracellular staining in CD11c+ LCs, and the results from five different donors are summarized (C).
(D) mLCs were preincubated with the supernatants from NHEKs treated with or without HSV-2, and then exposed to R5 HIV. HIV p24+ cells were assessed in
langerin+ CD11c+ mLCs at day 7.
(A, C, and D) Representative flow cytometric analyses are shown. (A and D) Results are shown as means ± SD (n = 3) (**p < 0.01). See also Figure S1.
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Because only a single layer of columnar epithelium guards the
endocervix and the transformation zone, the mucosal barrier
can be easily breached bymechanisms such as themicrotrauma
associated with sexual intercourse, which provides immediate
access to target cells, especially CD4+ T cells, in the submucosa
(Haase, 2010). Indeed, it has been shown that following mucosal
exposure to high doses of SIV, virus can gain access through
breaks in the mucosal epithelial barrier and infect resting CD4+
T cells in the submucosa (Haase, 2010). Since molecules target-
ing CCR5 completely protected against mucosal transmission of
SHIV (Lederman et al., 2004), CD4/CCR5-mediated de novo
infection of LCs and/or CD4+ T cells is considered to be a major
pathway involved in sexual transmission of HIV.
Several mechanisms have been proposed to explain en-
hanced sexual transmission of HIV during active STD infection,
including breakdown of epithelial barriers (i.e., ulceration) with
direct inoculation of HIV into the blood (Cunningham et al.,
1985), presence of inflammatory leukocytes that act as targets
(Zhu et al., 2009), and coinfection of cells by HIV and STD path-
ogens. Biological mechanisms responsible for greater HIV trans-
mission rates in the presence of genital herpes infections,78 Cell Host & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Ihowever, are as of yet unknown. Recently, we and others have
suggested that HIV susceptibility of LCs could be directly
enhanced by pathogens and indirectly enhanced by inflamma-
tory factors during STD, thereby leading to more likely sexual
transmission of HIV (de Jong et al., 2008; Ogawa et al., 2009).
In this report, we found that HSV-2 primarily infected epithelial
cells and then markedly enhanced HIV infection in adjacent
LCs. Interestingly, mechanistic studies revealed that LL-37
produced by HSV-2-infected epithelial cells upregulated CD4
and CCR5 on the surface of bystander LCs, thereby enhancing
HIV infection in these cells. These findingsmay lead to new strat-
egies designed to block sexual transmission of HIV.
RESULTS
HSV-2 Indirectly Enhances HIV Susceptibility in LCs via
Interaction with Epithelial Cells
We first examined whether HSV-2 modulates HIV susceptibility
of LCs by using an ex vivo skin explant model, whereby resident
LCs within epithelial tissue are exposed to HIV and then allowed
to emigrate from tissue, thus mimicking conditions that occur
following mucosal exposure to HIV (Kawamura et al., 2000).nc.
Figure 2. HSV-2 Increases Expression of
Human b Defensin-2, Defensin-3, Defensin-
4, and LL-37 in Normal Human Epithelial
Cells
HIV-1 (105 TCID50), HSV-2 (13 10
4 13 106 PFU),
and heat-inactivated HSV-2 (1 3 104  1 3 106
PFU) were exposed to NHEKs for 1 hr and then
washed twice. Cells were incubated in culture
medium for 12 hr, and the mRNA expression of
indicated AMPswas determined by qPCR. Results
are shown as mean relative mRNA expressions
(B) from three different experiments andmean the
average (C) of those (*p < 0.05; **p < 0.01). See
also Figure S2.
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LL-37 Enhances HIV Infection of Langerhans CellsEpidermal sheets obtained from suction blister roofs were
exposed to HSV-2 strain G at 1 3 106 PFU/tissue for 1 hr, and
then exposed to R5-tropic HIV-1BaL for 2 hr. Three days later,
to quantify numbers of HIV-infected LCs at the single-cell
level, cells emigrating from the explants were stained with anti-
CD11c, anti-langerin, and anti-HIV p24 mAbs. Intracellular
staining for HIV p24 represents productive HIV replication within
LCs, since expression can be completely blocked by AZT
(Kawamura et al., 2003). The numbers of LCs emigrating from
individual explants were determined, and the mean yield ± SD
was HSV/HIV; 1.04 ± 0.25 3 104, HSV/HIV+; 1.13 ±
0.31 3 104, HSV+/HIV; 1.25 ± 0.27 3 104; and HSV+/HIV+;
1.21 ± 0.25 3 104 (n = 3). Thus, the number of LCs recovered
from the skin explants was not significantly affected by HSV-2
or HIV exposure. However, preincubation of epithelial sheets
with HSV-2 significantly increased the percentage of HIV p24+
cells within langerin+ CD11c+ LCs approximately 3-fold as com-
pared to LCs emigrating from nonexposed epithelial sheets
(Figure 1A). The results of 11 separate experiments with different
skin donors are summarized in Figure 1 B (mean percentage HIV
p24+ LCs ± SD = 0.61 ± 0.31 with no HSV-2; 1.85 ± 0.79 with
HSV-2 preincubation, p = 0.0002, n = 11). To assess the ratio
of individual HSV-2- and/or HIV-infected LCs emigrating from
explants, cells were collected from cultures and stained with
anti-CD11c, anti-HSV gD, and anti-HIV p24 mAbs. A recent
study in mice showed that HSV impeded emigration of infected
LCs by inducing apoptosis and by blocking E-cadherin downre-
gulation (Miller et al., 2011b). Consistent with this finding, the
percentage of HSV-2-infected emigrating LCs was much less
when compared with LCs that remained within explants at day
3 (Figure 1C and see Figure S1 online). More importantly, we
found that HSV-2/HIV-coinfected emigrating LCswere rarely de-
tected (mean percentage of HIV-1 p24+/HSV-2 gD+ LCs ± SD =
0.04 ± 0.02, n = 5, Figure 1C), suggesting that HSV may not
directly modulate HIV susceptibility in LCs. Indeed, supernatants
from epithelial cell cultures of normal human epidermal keratino-
cytes (NHEKs) treatedwith HSV-2 also increased the percentage
of HIV p24+ monocyte-derived LCs (mLCs), even though mLCs
were not exposed to HSV-2 (Figure 1D). Of note, the magnitude
of HIV susceptibility in mLCs enhanced by HSV-treated NHEK
supernatants was comparable to that in emigrating LCs in theCell Host & Microbe 13, 77–8epithelial explant experiments. Enhance-
ment of HIV infection by supernatants
from HSV-2-treated NHEKs was depen-dent on the dose of HSV-2, and supernatants from heat-inacti-
vated HSV-2-treated NHEKs did not affect HIV susceptibility
in mLCs (Figure S2). HIV susceptibility in mLCs was also
enhanced when we infected NHEKs with a second HSV-2 strain,
186 (data not shown). Taken together, these results suggest
that HSV-2 indirectly mediates HIV infection of epidermal LCs
by a soluble factor or factors released by HSV-2-infected
epithelial cells.
HSV-2 Augments the Production of Antimicrobial
Peptides from Keratinocytes, and LL-37 Enhances HIV
Infection in LCs
In STDs, antimicrobial peptides (AMPs), including defensins and
cathelicidin, are the key effectormolecules ofmucosal innate and
adaptive immunity. Human vaginal epithelial cells and epidermal
keratinocytes can produce human a defensin-5 (HD5), HD6 and
human b defensin-1 (hBD1), hBD2, hBD3, hBD4, and the sole
cathelicidin in humans, LL-37. Certain defensins (e.g., hBD1)
are expressed constitutively, and others (e.g., hBD2 and hBD3)
show increased expression in response to inflammation or infec-
tion (Klotman and Chang, 2006). Several reports have indicated
that several of these AMPs modulate HIV infectivity in peripheral
blood mononuclear cells (PBMC) or in CD4+ T cells (Bergman
et al., 2007; Klotman et al., 2008; Quin˜ones-Mateu et al., 2003;
Sun et al., 2005). Thus, we investigated whether HSV-2 induced
AMPs production in keratinocytes. NHEKs were incubated with
HSV-2 (1 3 104  1 3 106 PFU) or HIV-1 (1 3 105 TCID50), and
relative mRNA expression levels of AMPs were determined
by quantitative RT-PCR. Interestingly, HSV-2 significantly in-
creased the expression of hBD2, hBD3, hBD4, and LL-37,
whereas neither HIV nor heat-inactivatedHSV-2 affected expres-
sion of hBD3, hBD4, and LL-37 (Figure 2).
To determine whether keratinocyte-derived AMPs affect HIV
susceptibility of LCs, mLCs were stimulated with AMPs or
TNF-a, as a positive control, for 24 hr before exposure to
HIV-1. Strikingly, only LL-37 significantly increased the per-
centage of HIV p24+ mLCs (Figure 3A). This infection-enhancing
effect of LL-37 was observed in a dose-dependent manner,
utilizing concentrations of LL-37 observed in physiologic condi-
tions (Ong et al., 2002; Yamasaki et al., 2007) (Figure 3B). Inter-
estingly, LL-37 also significantly upregulated surface expression6, January 16, 2013 ª2013 Elsevier Inc. 79
Figure 3. LL-37 Enhances HIV Susceptibility
in mLCs
mLCs were stimulated with the indicated AMPs or
rhTNF-a 24 hr prior to HIV exposure. To assess HIV
infection levels, mLCs were collected 7 days after
HIV exposure, and HIV p24+ cells were quantified
in langerin+ CD11c+ mLCs.
(A) Each circle indicates the normalized per-
centage of positive cells for HIV p24; mean values
obtained from different donors are shown as
horizontal marks.
(B) The percentage of positive cells for HIV p24 in
langerin+ CD11c+ mLCs and representative flow
cytometric analyses following LL-37 stimulation.
(C) NHEKs were exposed to HSV-2 or heat-
inactivated HSV-2. Following culture for the
indicated number of days, LL-37 levels were
measured in supernatants by ELISA. Results are
shown as means ± SD (n = 3) (*p < 0.05).
(D) NHEKs were treated with HSV-2 for 3 days and
then lysed. The expression of hCAP18, KLK5, and
LL-37 was determined by western blot analysis.
All data shown represent at least two separate
experiments. See also Figure S3.
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LL-37 Enhances HIV Infection of Langerhans Cellsof CD86, CD83, and CCR7 on mLCs (Figure S3), indicating that
LL-37 induces LC maturation.
To confirm whether HSV-2-treated NHEKs could produce
LL-37 protein, we measured LL-37 protein levels in culture
supernatants from NHEKs treated with medium alone, HSV-2,
or heat-inactivated HSV-2 by ELISA. HSV-2 significantly induced
production of LL-37 in NHEKs, which peaked at day 5 (Fig-
ure 3C). Expression levels of kallikrein 5 (KLK5) have been shown
to parallel induction of LL-37 in KCs, since the activity of cathe-
licidin is controlled by enzymatic processing of the proform
hCAP18 to a mature peptide LL-37 by KLK5, a serine protease
(Morizane et al., 2010; Yamasaki et al., 2006). Therefore, we
measured protein levels of LL-37, hCAP18, and KLK5 in NHEKs
treated with medium alone or HSV-2. As shown in Figure 3D,
HSV-2 induced production of LL-37 in NHEKs. Similarly,
HSV-2 increased expression of hCAP18 as well as KLK5, and
these protein levels coincided with the induction of LL-37 in
NHEKs (Figure 3D).
To further confirm the participation of LL-37 in this enhance-
ment, we used RNA interference (siRNA) to block LL-37 produc-
tion. Protein levels were quantified by western blotting followed
by densitometry analysis. Transfection of siRNA targeting LL-37
induced an efficient knockdown in NHEKs (55%downregulation;
Figure 4A). In line with the results of western blot analyses,
siRNA-mediated interference of LL-37 in NHEKs significantly
reduced enhancement of HIV infection in mLCs by supernatants
from HSV-2-treated NHEKs, in comparison with control siRNA
targeting an irrelevant sequence (Figure 4B). Based on these
results, we conclude that enhanced HIV infection in mLCs by
supernatants from HSV-2-treated NHEKs is, at least in part,
mediated by LL-37.
Recently, TNF-a derived from KCs has also been shown to
enhance HIV susceptibility of LCs (de Jong et al., 2008; Ogawa
et al., 2009). In our experiments, however, TNF-a was not de-
tected in culture supernatants from NHEKs treated by HSV-2
(data not shown), consistent with a recent report (de Jong80 Cell Host & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Iet al., 2010). In addition, preincubation of supernatants from
HSV-2-treated NHEKs with an anti-TNF-a neutralizing mAb,
prior to exposing mLCs, did not affect HIV susceptibility in
mLCs (Figure S4).
LL-37 Enhances Surface Expression of CD4 and CCR5
on mLCs
Previous studies have revealed that langerin expressed on LCs is
a natural barrier to HIV infection because HIV virions captured by
langerin are internalized into LC Birbeck granules and degraded
(de Witte et al., 2007). In addition, APOBEC3G (A3G) and SAM
domain and HD domain 1 (SAMHD1) has been recently shown
to function as a potent postentry cellular restriction factor for
HIV in DCs or LCs (Hrecka et al., 2011; Laguette et al., 2011;
Ogawa et al., 2009; Pion et al., 2006). Therefore, we next exam-
ined whether LL-37 affects the expression levels of these mole-
cules in mLCs. LL-37 stimulation did not affect the expression of
langerin, A3G, or SAMHD1 (Figures 4C and 4D and Figure S5).
In contrast, LL-37 significantly increased surface expression of
CD4 and CCR5 on mLCs (Figure 4C). In addition, siRNA-medi-
ated interference of LL-37 in NHEKs significantly reduced the
enhancement of surface expression of CD4 and CCR5 in
mLCs by supernatants from HSV-2-treated NHEKs, in compar-
ison with control siRNA targeting an irrelevant sequence (Fig-
ure 4C). Thus, our results suggest that LL-37 enhances HIV
infection in LCs by increasing surface expression of HIV recep-
tors, rather than by modulating restriction factors such as lan-
gerin, A3G, or SAMHD1.
Since LL-37 upregulated surface expression of CD4 and
CCR5 in LCs, we next examined whether LL-37 specifically
enhanced R5-tropic HIV entry into LCs by using single-round
infection assays with pseudotyped viruses containing a lucif-
erase reporter and different envelope proteins (Env): Env from
either R5 HIV-1 (JR-FL; R5), X4 HIV-1 (IIIB; X4), or vesicular
stomatitis virus (VSV-G). As expected, we found that LL-37
pretreatment enhanced the infectivity of mLCs to R5-VSV innc.
Figure 4. Silencing of LL-37 in HSV-2-
Infected NHEKs Abrogates Enhanced HIV
Infectivity in mLCs
(A) NHEKs were transfected with control or LL-37
siRNA and then exposed with or without HSV-2.
Cells were lysed and then determined the ex-
pression of LL-37 by western blot analysis.
(B) mLCs were incubated with indicated culture
supernatants for 12 hr and then exposed to R5
HIV. mLCs were collected 7 days after the HIV
exposure, and HIV p24+ cells were assessed in
langerin+ CD11c+ mLCs. Representative flow cy-
tometric analyses of CD11c and p24 mAb double-
stained cells are shown.
(C) mLCs were stimulated with TNF-a or LL-37
at the indicated concentrations or indicated
culture supernatants for 24 hr. The expression of
CD4, CCR5, and langerin was assessed by flow
cytometry.
(D) The expression of A3G was determined
by western blot analysis. Results are shown as
means ± SD (n = 3) (*p < 0.05). All data shown
represent at least two separate experiments. See
also Figure S4.
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with VSV-G (Figure 5A). Consistent with previous findings (Kawa-
mura et al., 2001), mLCs were resistant to X4-VSV, even after LL-
37 treatment. These results provide direct evidence that LL-37,
which upregulates surface expression of CD4 and CCR5 in
LCs, promotes increased R5 HIV entry into these cells. Further-
more, similar effects of LL-37 were observed when mLCs were
infected with R5 HIV primary isolates: JR-FL and AD8 (Figures
5B and 5C).
LL-37 Decreases HIV Infectivity in mDCs
We next examined whether LL-37 affects HIV infectivity in non-
LC-like DCs. Similar to mLCs, LL-37 significantly upregulated
surface expression of CD86 and CCR7 on monocyte-derived
DCs (mDCs, Figure S3), indicating that LL-37 induces DC
maturation. In marked contrast to mLCs, however, there was
inhibition of HIV infection in mDCs when these cells were prein-
cubated with LL-37 prior to HIV exposure (Figure 6A), indicating
that LL-37 effects on HIV infectivity are differentially regulated in
LCs andDCs. LL-37 did not affect CD4 or A3G expression in DCs
but markedly downregulated surface expression of CCR5 and
DC-SIGN (Figures 6B and 6C). It has been shown that DC-
SIGN binds HIV and plays a critical role for HIV replication in
mDCs (Gringhuis et al., 2010). These results, in contrast to
mLCs, suggest that decreased HIV infection levels observed in
LL-37-treated mDCs may be due to downregulation of DC-
SIGN and/or CCR5 on their cell surfaces. Taken together, our
results indicated the presence of exclusive machinery to aug-
ment HIV infection by LL-37 in LC in contrast to that in CD4+
T cells (Bergman et al., 2007) and mDCs.
LL-37 Enhances HIV Transmission from LCs to CD4+
T Cells
We next examined whether LL-37 affected HIV transmission
from LCs to cocultured CD4+ T cells. mLCs or mDCs were stim-
ulated with AMPs or TNF-a for 24 hr, exposed to HIV-1Ba-L, andCell Hthen cocultured with allogeneic CD4+ T cells for 12 days. Consis-
tent with results showing that LL-37 increases HIV infection
levels in mLCs (Figure 3A), preincubation of mLCs with LL-37
significantly enhanced subsequent HIV transmission from
mLCs to CD4+ T cells in a dose-dependent manner; prein-
cubation with other AMPs did not affect HIV transmission levels
in mLC-T cell cocultures (Figure 7A). By contrast, HIV transmis-
sion from mDCs to CD4+ T cells was significantly decreased
by preincubation of mDCs with LL-37 (Figure 7B), consistent
with decreased HIV infection levels in LL-37-treated mDCs
(Figure 6A).
DISCUSSION
LCs are generally believed to be one of the cell types that plays
a pivotal role in the dissemination of virus during sexual transmis-
sion of HIV. To understand the biologic mechanisms by which
HSV-2 increases acquisition of HIV, we tested the hypothesis
that HSV-2 modulates LC susceptibility to HIV. As expected,
we found that HSV-2 enhances HIV susceptibility of LCs within
epithelial tissue (Figure 1), consistent with a recent finding that
HSV-2 directly enhances HIV susceptibility in LCs (de Jong
et al., 2010). However, in our ex vivo explant model, the per-
centage of HSV/HIV-coinfected LCs was quite low. Instead,
our findings suggested that HSV-2 increases HIV susceptibility
in LCs by indirect (i.e., epithelial cell-dependent) mechanisms.
More specifically, we show here that LL-37 produced by HSV-
2-infected epithelial cells enhances HIV infection of LC, most
likely by increasing surface expression of CD4 and CCR5 on
these cells.
There are conflicting prior reports on how defensins affect HIV
infectivity. A variety of anti-HIV activities for hBD2 and hBD3
have been reported, including direct inhibition of virions, indirect
inhibition of HIV replication, and downregulation of HIV corecep-
tors (Klotman andChang, 2006;Quin˜ones-Mateu et al., 2003). By
contrast, other studies have shown increased HIV infection ofost & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Inc. 81
Figure 5. LL-37 Enhances mLCs Sus-
ceptibility to R5-HIV and R5 HIV Primary
Isolates
mLCs were stimulated with LL-37 at the indicated
concentration or hBD2 as control, and then
exposed to pseudotyped viruses (R5-HIV, X4-HIV
or VSV-G-HIV) for 72 hr (A) or R5 HIV primary
isolates (JR-FL or AD8) for 2 hr (B and C). To
assess pseudotyped virus infection levels, the
average luciferase activity was calculated as rela-
tive light units (A). To assess primary HIV infection
levels, mLCs were collected 7 days after the HIV
exposure, and HIV p24+ cells were assessed in
langerin+ CD11c+ mLCs (upper panels, % of
positive cells for HIV p24 in langerin+ CD11c+
mLCs; and lower panels, representative flow cy-
tometric analyses following LL-37 stimulation).
Results are shown as means ± SD (*p < 0.05; **p <
0.01). All data shown represent at least two
separate experiments. See also Figure S5.
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surface HIV coreceptor expression by hBD1 and hBD2 (Klotman
et al., 2008; Sun et al., 2005). These conflicting reports might be
due to differences in experimental conditions or cell types used
(e.g., PBMC or CD4+ T cells). Interestingly, we found that, unlike
PBMC and CD4+ T cells, human b defensins did not affect HIV
infectivity of LCs (Figure 3). Although no significant differences
were detected, hBD2 andHD5 tended to decrease HIV infectivity
of LCs. In addition, consistent with a previous finding that LL-37
inhibits HIV replication in CD4+ T cells (Bergman et al., 2007), we
found that LL-37 significantly inhibited HIV infectivity in DCs,
probably through downregulation of surface DC-SIGN expres-
sion (Figure 6). By contrast, LL-37 upregulated surface ex-
pression of CD4 and CCR5 in LCs, and upregulation strongly
correlated with the increased R5 HIV entry and infection within
these cells (Figure 4 and Figure 5). Thus, these findings clearly
indicate that the effects of AMPs on HIV infectivity are differen-
tially regulated depending on the target cell type.
We found that HSV-2 infection in epithelial cells induced the
production of soluble LL-37 that had potent enhancing effects
on HIV infectivity in LCs. siRNA-mediated interference of LL-37
transcription blocked, at least in part, increased HIV infectivity.
We hypothesize that when HSV-2 infection occurs in genital
mucosa, LL-37 produced by HSV-infected epithelial cells aug-
ments HIV susceptibility of LCs, thereby leading to enhanced
sexual transmission of HIV. Notably, a recent study has shown
that cervicovaginal levels of LL-37 were associated with in-
creased HIV acquisition in Kenyan sex workers (Levinson et al.,
2009), a clinical finding that supports our hypothesis. Thus,
HSV-2 can mediate both direct enhancing effects on HIV sus-
ceptibility in LCs as well as indirect enhancing effects via
LL-37 production as shown here. These results further our
understanding of the complex biologic events that occur during
the early stages of sexual transmission of HIV.82 Cell Host & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Inc.EXPERIMENTAL PROCEDURES
Reagents
Cells were stimulated with synthetic AMPs
(Peptide Institute) for 24 hr at the following concen-trations: a defensin-5 (50 mg/ml), b defensin-1 (50 mg/ml), b defensin-2
(50 mg/ml), b defensin-3 (5 mg/ml), b defensin-4 (50 mg/ml), and LL-37
(50 mg/ml). Recombinant human (rh) TNF-a (5 mg/ml, R&D Systems) was
used as a positive control in some experiments. Anti-TNF-a neutralizing
mAbs (clone; MABTNF-A5) were purchased from BD PharMingen and used
at a final concentration of 1 mg/ml.
Cell Preparation
NHEKs were purchased from Kurabo and cultured with EpiLife supplemented
with insulin (10 mg/ml), rhEGF (epidermal growth factor, 0.1 ng/ml), hydrocor-
tisone (0.5 mg/ml), gentamicin (50 mg/ml), amphotericin B (50 ng/ml), and
bovine pituitary extract (0.4% V/V) (EpiLife-KG2 medium, all from Kurabo) in
a humidified atmosphere with 5% CO2 at 37C.
mLCs and mDCs were cultured from adult plastic-adherent PBMCs as
described previously (Kawamura et al., 2001). Briefly, monocytes were iso-
lated by depletion of magnetically labeled nonmonocytes (Monocyte Isolation
Kit II, Miltenyi Biotec) from plastic-adherent PBMCs obtained from healthy
blood donors. Monocytes were cultured in RPMI 1640 (GIBCO BRL)
supplemented with 10% heat-inactivated FBS (Cell Culture Technologies),
100 U/ml penicillin (GIBCO BRL), 100 mg/ml streptomycin (GIBCO BRL),
2 mM L-glutamine (GIBCO BRL) (complete medium) supplemented with
1,000 U/ml rhGM-CSF (R&D Systems), 1,000 U/ml rhIL-4 (R&D Systems),
and with mLCs or without mDCs 10 ng/ml human platelet-derived TGF-b1
(R&D Systems) for 7 days. Since we have previously found the expression
levels of E-cadherin+ cells and langerin+ cells in mLCs to be approximately
90% and 35%, respectively (Kawamura et al., 2001), cell sorting was per-
formed at day 7 to isolate highly purified langerin-positive mLCs followed
by staining with anti-langerin mAb (Immunotech), as previously described
(Ogawa et al., 2009). Alternatively, mLCs were identified by gating langerin-
positive cells in flow cytometric analyses.
HSV-2 Exposure of Cells In Vitro and Skin Explants Ex Vivo
Purified, pelleted, and titered HSV-2 G strain (stock at 108 PFU/ml) was
purchased from Advanced Biotechnologies. HSV-2 strain 186 (stock at
1.5 3 107 PFU/ml) was a gift from Yukihiro Nishiyama (Nagoya University
Graduate School of Medicine, Nagoya, Japan). A total of 2 3 105 mLCs or
mDCs, or 5 3 106 NHEK, were cultured with different concentrations of
HSV-2 (104–6 PFU) at 37C, and then washed three times. In some experiments
using the supernatants from NHEKs treated by HSV-2, culture supernatants
Figure 6. LL-37 Decreases HIV Susceptibility in mDCs
(A) mDCs were stimulated with the indicated AMPs or rhTNF-a 24 hr prior to
HIV exposure. To determine HIV infection levels, mDCs were collected 7 days
after HIV exposure, and HIV p24+ cells were assessed in CD11c+ mDCs.
Representative flow cytometric analyses are shown.
(B) mDCs were stimulated with TNF-a or LL-37 at the indicated concentrations
for 24 hr. The expression of CD4, CCR5, and DC-SIGN was assessed by flow
cytometry.
(C) The expression of A3G was determined by western blot analysis. Results
are shown as means ± SD (n = 3) (*p < 0.05; **p < 0.01). All data shown
represent at least two separate experiments.
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0.1 mm Supor Membrane to remove viruses. For control infection, the same
batch of virus was inactivated at 56C for 10 min and the same volume as
the active virus was added to cells. For exposure of epithelial tissue explants,
50 ml droplets containing different concentrations of HSV-2 were placed on the
inside surfaces of sterile plastic culture dish covers. Explants were draped over
droplets with the basal epithelial cell surface facing downward. Virus and
explants were incubated together in this manner at 37C in a humidified 5%
CO2 environment for 1 hr, and then washed three times with cold PBS.
HIV Infection of Cells In Vitro and Skin Explants Ex Vivo
Purified, pelleted, and titered HIV-1Ba-L, an R5 HIV laboratory isolate (stock at
TCID50 of 10
7.17/ml and 1.8 3 1010 virus particles/ml), was purchased from
Advanced Biotechnologies. Molecular clones R5 HIV primary isolates (JR-FL
and AD8) were prepared as described previously (Koyanagi et al., 1997;
Theodore et al., 1996). Briefly, 293T cells were transfected with 30 mg of
HIV-1 proviral DNA. One day after transfection, the medium was replaced
with fresh RPMI 1640 medium supplemented with 10% FCS, and then
2 days later, the viruses were recovered, filtered through a membrane (pore
size, 0.22 mm), and assayed for HIV-1 p24 gag content by ELISA. The titer
of each virus stock was determined by endpoint titer determination of 3-fold
limiting dilution in triplicate on PHA-activated PBMC from a single donor.
Aliquots of the viral stocks (TCID50 of 9,004,929/ml; JR-FL and 7,746,147/
ml; AD8) were stored at minus 80C until use. For some experiments, 2 3
105 mLCs and mDCs were preincubated with various agonists, inhibitors,
HSV-2, or the supernatants from NHEKs treated by HSV-2, and then HIV-
1Ba-L at a 1/100 final dilution or R5 HIV primary isolates (JR-FL and AD8) at
TCID50 of 10
5/ml was added for 2 hr at 37C, as described previously
(Kawamura et al., 2001). After incubation, cells were harvested, washed threeCell Htimes in washing medium (HBSS containing 10% heat-inactivated FBS), re-
suspended in complete medium supplemented with GM-CSF and IL-4, and
cultured for 7 additional days at the same cellular concentration. HIV-infected
cells were assessed by HIV p24 intracellular staining. Because the variability in
the infection levels was most likely due to the CCR5 heterogeneity in the
donors, HIV infection levels with mLCs and mDCs obtained from different
donors were not directly compared. Instead, HIV infection levels were ex-
pressed as a normalized percent of the positive cells for HIV p24 by using
a calculated fold difference as compared with the mean percent of the positive
cells for HIV p24 in untreated cells (Figure 3A). In some experiments, 2 3 104
HIV-infected mLCs or mDCs were cocultured with 2 3 106 allogeneic CD4+
T cells for 12 days, and supernatants were harvested every third day and
examined for HIV p24 protein content by ELISA (ZeptoMetrix) according to
the manufacturer’s instructions.
Epithelial sheets were obtained from suction blister roofs from HIV-negative
healthy donors. For infection of epithelial tissue explants, 50 ml droplets con-
taining HIV-1Ba-L at a 1/100 final dilution were placed on the inside surfaces
of sterile plastic culture dish covers, as described previously (Kawamura
et al., 2000). Explants were draped over droplets with the basal epithelial
cell surface facing downward. Virus and explants were incubated together in
this manner at 37C in a humidified 5% CO2 environment for 2 hr. Explants
were washed in three separate wells in 6-well plates containing sterile PBS
and then floated with the basal epithelial cell sides down in 12-well plates con-
taining 2 ml of complete medium, without exogenous stimulants or cytokines.
The emigrating cells from the epidermal sheets were collected 3 days after
the HIV exposure. In some experiments, epidermal cell suspensions were
prepared by limited trypsinization of epidermal sheets, as described previously
(Miller et al., 2011a).
Pseudotyped Virus Infection and Luciferase Assay
To prepare pseudotyped viruses with Env from either HIV-1 (IIIB, JR-FL, or
VSV), 293 T cells were cotransfected with the Env expression plasmid
DNA, pLET, pJRFLenv, or pMD.G, respectively, and with pNLLuc (an Env-
defective HIV-1NL4-3 carrying the luciferase gene) as described previously
(Sato et al., 2008). The culture supernatants were harvested and then filtrated
to produce virus solutions at 48 hr posttransfection. To measure the infectivity
of Env-pseudotyped virus, mLCs were incubated with JR-FL Env- or IIIB
Env-pseudotyped virus, containing 20 ngof p24CA, or VSVenvelope glycopro-
tein-pseudotyped virus, containing 0.5 ng of p24CA, for 72 hr. The Picagene
luciferase assay kit (Toyo Ink) was used to perform luciferase assays, following
the manufacturer’s protocols. Activity was measured with a 1420 ARVOSX
multilabel counter (Perkin Elmer) and normalized to the protein content of
each lysate, measured with a Coomassie (Bradford) protein assay kit (Pierce).
Flow Cytometry
Single-cell suspensions were stained using the following anti-human
mAb: anti-CD83 (BD Biosciences-PharMingen), anti-CD86 (BD Biosciences-
PharMingen), anti-CD4 (Beckman Coulter), anti-CCR5 (R&D), anti-DC-sign
(R&D), anti-CCR7 (R&D) directly conjugated to FITC, anti-langerin (Immuno-
tech) directly conjugated to PE, and anti-CD11c (Becton Dickinson) directly
conjugated to allophycocyanin. Cells were incubated with Abs for 30 min
at 4C and then washed three times in staining buffer and examined by
FACScaliber using propidium iodide (Sigma) to exclude the dead cells in the
surface staining.
To specifically identify HIV- or HSV-infected cells on a single-cell level, HIV
p24 or HSV gD intracellular staining was performed, respectively. Epidermal
LCs, mLCs, andmDCswere collected at the indicated days after HIV exposure
and then washed three times in staining buffer, and then incubated with
10 mg/ml allophycocyanin-conjugated mouse anti-human CD11c mAb, and
with mLCs or without mDCs PE-conjugated mouse anti-human langerin
mAb and for 30 min at 4C. Cells were then washed three times in staining
buffer and fixed and permeabilized with Cytofix/Cytoperm reagents (BD
Biosciences-PharMingen) for 20 min at 4C. Cells were then washed three
times in Perm-Wash (BD Biosciences-PharMingen), incubated with FITC- or
PE-conjugated mouse anti-HIV p24 mAb (Beckman Coulter) and/or FITC-
conjugated mouse anti-HSV gD mAb (Argene) diluted for 30 min at 4C, and
washed three times in Perm-Wash, with the quantified numbers of HIV- or
HSV-infected cells determined by FACScaliber.ost & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Inc. 83
Figure 7. LL-37 Enhances HIV Transmission
from mLCs to T Cells
mLCs (A) or mLCs and mDCs isolated from the
same donor (B) were stimulated with the indicated
AMPs or rhTNF-a 24 hr prior to HIV exposure. HIV-
infected mLCs or mDCs were cocultured with
allogeneic CD4+ T cells, and p24 protein levels in
culture supernatants were assessed by ELISA on
the indicated days. Results are shown as means
plus or minus SD (n = 3). *p < 0.05; **p < 0.01. All
data shown represent at least two separate
experiments.
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The delivery of siRNA into NHEKs was performed by DharmaFECT 3 siRNA
Transfection Reagent (Dharmacon). Cells were transfected with siRNAs at
a final concentration of 50 nM. The siRNAs used in this study were ON-
TARGETplus nontargeting pool (Dharmacon #D 001810–10) for control
siRNA and ON-TARGETplus SMARTpool siRNA Human CAMP (Dharmacon
#L-019790–00) for LL-37 siRNA.
Real-Time Quantitative RT-PCR Analysis
Relative mRNA expression was determined by real-time PCR using an ABI
PRISM 5500 Sequence Detection System (Applied Biosystems) with SYBR
Green I dye (QIAGEN) according to the manufacturer’s instructions. Total
RNA was isolated using TRIzol (Invitrogen Life Technologies), and cDNA was
synthesized using the SuperScript system (Invitrogen Life Technologies).
Primers corresponding to human a defensin-5, defensin-6, human b defen-
sin-1, b defensin-2, b defensin-3, b defensin-4, LL-37, and GAPDH were
designed by Takara Bio, Inc. Cycle threshold numbers (Ct) were derived
from the exponential phase of the PCR amplification. Fold differences in the
expression of gene x in the cell populations y and z were derived by 2k, where
k = (Ctx  CtG3PDH)y  (Ctx  CtG3PDH)z.
ELISA
NHEKs were exposed to live HSV-2 (106 PFU) or heat-inactivated HSV-2
for 1 hr, and then washed three times. Following culture in medium for the indi-
cated days, the culture supernatants were collected after centrifugation and
stored at 80C for LL-37 and TNF-a measurement. The concentration of
human LL-37 (Hycult biotechnology) and TNF-a (R&D Systems) in the culture
supernatants was measured by ELISA. For measurement of HIV p24 protein
levels, supernatants were collected, inactivated with Triton X-100 (Sigma-
Aldrich; 2% final concentration), and kept frozen until measurements of HIV
p24 protein levels were performed by ELISA (ZeptoMetrix).
Western Blot Analysis
Proteins of the cells were extracted using 15 min incubation in complete lysis
buffer containing a protease inhibitor. Equal amounts of protein were separated
by SDS-PAGE and transferred onto a transfer membrane (Daiichikagaku).
Western blot was performed in order to detect hCAP18 (2.0 mg/ml, Abcam),
KLK5 (2.0 mg/ml, R&D Systems), LL-37 (2.0 mg/ml, Santa Cruz), A3G (2.5 mg/ml,84 Cell Host & Microbe 13, 77–86, January 16, 2013 ª2013 Elsevier Inc.Abcam), and SAMHD1 (2.0 mg/ml, Abcam). Blots
were incubated with the HRP-linked secondary
antibody. Analyses were performed using the HRP
western blot detection system (Pierce), and band
intensities were calculated using ImageJ software.
Statistical Analyses
Significant differences between experimental
groups were analyzed by Student’s t test (one-
tailed). p values less than 0.05 were considered
significant.
Study Approval
The Institutional Review Board of the University
Hospital (University of Yamanashi, Yamanashi,Japan) approved the acquisition of human tissues, and informed consent
was obtained from all skin donors.
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